AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SHPH
  4. [Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity

[Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Timothy J. Lorber, Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), was granted a total of 54,094 restricted stock units (RSUs) in transactions dated 08/08/2025. Each RSU represents a contingent right to receive one share of common stock and the grants were reported on a Section 16 Form 4.

The awards are split into two grants: 29,240 RSUs that vest one-third on each of 08/08/2026, 08/08/2027 and 08/08/2028, and 24,854 RSUs that vest on 02/08/2026. Both grants show an acquisition price of $0 and are held in a direct ownership form.

Timothy J. Lorber, Chief Financial Officer di Shuttle Pharmaceuticals Holdings, Inc. (SHPH), ha ricevuto un totale di 54,094 unit脿 di azioni vincolate (RSU) in operazioni datate 08/08/2025. Ciascuna RSU rappresenta il diritto condizionato a ricevere una azione ordinaria e le assegnazioni sono state dichiarate nel Section 16 Form 4.

Gli incentivi sono suddivisi in due tranche: 29,240 RSU che maturano per un terzo ciascuna in data 08/08/2026, 08/08/2027 e 08/08/2028, e 24,854 RSU che maturano il 02/08/2026. Entrambe le tranche indicano un prezzo di acquisizione di $0 e sono detenute in forma di propriet脿 diretta.

Timothy J. Lorber, Director Financiero de Shuttle Pharmaceuticals Holdings, Inc. (SHPH), recibi贸 un total de 54,094 unidades restringidas de acciones (RSU) en operaciones fechadas el 08/08/2025. Cada RSU otorga el derecho contingente a recibir una acci贸n ordinaria y las concesiones se informaron en un Section 16 Form 4.

Los premios se dividen en dos concesiones: 29,240 RSU que se consolidan en tercios el 08/08/2026, 08/08/2027 y 08/08/2028, y 24,854 RSU que se consolidan el 02/08/2026. Ambas muestran un precio de adquisici贸n de $0 y se mantienen en forma de propiedad directa.

Timothy J. Lorber, Shuttle Pharmaceuticals Holdings, Inc. (SHPH)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO), 电� 08/08/2025鞛� 瓯半灅搿� 齑� 54,094臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU电� 氤错喌欤� 1欤茧ゼ 氚涭潉 靾� 鞛埖鐢 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 頃措嫻 攵�鞐鐢 Section 16 Form 4鞐� 氤搓碃霅橃棃鞀惦媹雼�.

靾橃棳电� 霊� 瓯挫溂搿� 雮橂墿雼堧嫟: 29,240 RSU电� 08/08/2026, 08/08/2027, 08/08/2028鞐� 臧侁皝 1/3鞌� 氩犾姢韺呺悩瓿�, 24,854 RSU电� 02/08/2026鞐� 氩犾姢韺呺惄雼堧嫟. 霊� 瓯� 氇憪 旆摑 臧�瓴╈澊 $0鞙茧 響滌嫓霅橂┌ 歆侅为 靻岇湢 順曧儨搿� 氤挫湢霅╇媹雼�.

Timothy J. Lorber, directeur financier de Shuttle Pharmaceuticals Holdings, Inc. (SHPH), s'est vu attribuer un total de 54,094 unit茅s d'actions restreintes (RSU) dans des op茅rations dat茅es du 08/08/2025. Chaque RSU repr茅sente un droit conditionnel de recevoir une action ordinaire et les attributions ont 茅t茅 d茅clar茅es dans un Section 16 Form 4.

Les attributions se r茅partissent en deux lots : 29,240 RSU qui se d茅bloquent par tiers les 08/08/2026, 08/08/2027 et 08/08/2028, et 24,854 RSU qui se d茅bloquent le 02/08/2026. Les deux lots indiquent un prix d'acquisition de $0 et sont d茅tenus sous forme de propri茅t茅 directe.

Timothy J. Lorber, Chief Financial Officer von Shuttle Pharmaceuticals Holdings, Inc. (SHPH), wurde in Transaktionen vom 08/08/2025 mit insgesamt 54,094 Restricted Stock Units (RSUs) ausgestattet. Jede RSU gew盲hrt bedingt das Recht, eine Stammaktie zu erhalten; die Zuteilungen wurden im Section 16 Form 4 gemeldet.

Die Zuwendungen sind in zwei Tranches aufgeteilt: 29,240 RSU, die zu jeweils einem Drittel am 08/08/2026, 08/08/2027 und 08/08/2028 f盲llig werden, und 24,854 RSU, die am 02/08/2026 f盲llig werden. Beide Tranches weisen einen Erwerbspreis von $0 aus und werden in direktem Eigentum gehalten.

Positive
  • CFO Timothy J. Lorber was granted a total of 54,094 RSUs (29,240 and 24,854) reported on 08/08/2025
  • Each RSU represents the contingent right to one share of common stock, explicitly stated in the filing
  • Vesting schedules are specified: one award vests one-third annually (08/08/2026, 08/08/2027, 08/08/2028) and the other vests on 02/08/2026
  • Ownership form for both awards is direct (D), as reported in Table II
Negative
  • None.

Insights

TL;DR: CFO received 54,094 RSUs with defined vesting dates, split into two awards with multi-date vesting.

The filing discloses two RSU awards to CFO Timothy J. Lorber totaling 54,094 RSUs. One award of 29,240 RSUs vests in three equal installments on 08/08/2026, 08/08/2027 and 08/08/2028; the other 24,854 RSUs vests on 02/08/2026. The awards are reported as acquired at $0 and held directly. From a compensation-design perspective, the staggered vesting dates define timing for potential share issuance but the filing contains no details on grant rationale, target compensation levels, or performance conditions.

TL;DR: Insider disclosure reports equity grants to an officer with explicit vesting schedule and direct ownership.

The Form 4 documents equity awards to an executive officer (CFO) and provides clear vesting dates and quantities: 29,240 RSUs with three-date vesting and 24,854 RSUs vesting on a single date. The form indicates direct beneficial ownership and $0 acquisition price. The disclosure meets Section 16 reporting requirements but does not include other governance details such as board approval language or equity plan identifiers within the provided text.

Timothy J. Lorber, Chief Financial Officer di Shuttle Pharmaceuticals Holdings, Inc. (SHPH), ha ricevuto un totale di 54,094 unit脿 di azioni vincolate (RSU) in operazioni datate 08/08/2025. Ciascuna RSU rappresenta il diritto condizionato a ricevere una azione ordinaria e le assegnazioni sono state dichiarate nel Section 16 Form 4.

Gli incentivi sono suddivisi in due tranche: 29,240 RSU che maturano per un terzo ciascuna in data 08/08/2026, 08/08/2027 e 08/08/2028, e 24,854 RSU che maturano il 02/08/2026. Entrambe le tranche indicano un prezzo di acquisizione di $0 e sono detenute in forma di propriet脿 diretta.

Timothy J. Lorber, Director Financiero de Shuttle Pharmaceuticals Holdings, Inc. (SHPH), recibi贸 un total de 54,094 unidades restringidas de acciones (RSU) en operaciones fechadas el 08/08/2025. Cada RSU otorga el derecho contingente a recibir una acci贸n ordinaria y las concesiones se informaron en un Section 16 Form 4.

Los premios se dividen en dos concesiones: 29,240 RSU que se consolidan en tercios el 08/08/2026, 08/08/2027 y 08/08/2028, y 24,854 RSU que se consolidan el 02/08/2026. Ambas muestran un precio de adquisici贸n de $0 y se mantienen en forma de propiedad directa.

Timothy J. Lorber, Shuttle Pharmaceuticals Holdings, Inc. (SHPH)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO), 电� 08/08/2025鞛� 瓯半灅搿� 齑� 54,094臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)毳� 攵�鞐皼鞎橃姷雼堧嫟. 臧� RSU电� 氤错喌欤� 1欤茧ゼ 氚涭潉 靾� 鞛埖鐢 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 頃措嫻 攵�鞐鐢 Section 16 Form 4鞐� 氤搓碃霅橃棃鞀惦媹雼�.

靾橃棳电� 霊� 瓯挫溂搿� 雮橂墿雼堧嫟: 29,240 RSU电� 08/08/2026, 08/08/2027, 08/08/2028鞐� 臧侁皝 1/3鞌� 氩犾姢韺呺悩瓿�, 24,854 RSU电� 02/08/2026鞐� 氩犾姢韺呺惄雼堧嫟. 霊� 瓯� 氇憪 旆摑 臧�瓴╈澊 $0鞙茧 響滌嫓霅橂┌ 歆侅为 靻岇湢 順曧儨搿� 氤挫湢霅╇媹雼�.

Timothy J. Lorber, directeur financier de Shuttle Pharmaceuticals Holdings, Inc. (SHPH), s'est vu attribuer un total de 54,094 unit茅s d'actions restreintes (RSU) dans des op茅rations dat茅es du 08/08/2025. Chaque RSU repr茅sente un droit conditionnel de recevoir une action ordinaire et les attributions ont 茅t茅 d茅clar茅es dans un Section 16 Form 4.

Les attributions se r茅partissent en deux lots : 29,240 RSU qui se d茅bloquent par tiers les 08/08/2026, 08/08/2027 et 08/08/2028, et 24,854 RSU qui se d茅bloquent le 02/08/2026. Les deux lots indiquent un prix d'acquisition de $0 et sont d茅tenus sous forme de propri茅t茅 directe.

Timothy J. Lorber, Chief Financial Officer von Shuttle Pharmaceuticals Holdings, Inc. (SHPH), wurde in Transaktionen vom 08/08/2025 mit insgesamt 54,094 Restricted Stock Units (RSUs) ausgestattet. Jede RSU gew盲hrt bedingt das Recht, eine Stammaktie zu erhalten; die Zuteilungen wurden im Section 16 Form 4 gemeldet.

Die Zuwendungen sind in zwei Tranches aufgeteilt: 29,240 RSU, die zu jeweils einem Drittel am 08/08/2026, 08/08/2027 und 08/08/2028 f盲llig werden, und 24,854 RSU, die am 02/08/2026 f盲llig werden. Beide Tranches weisen einen Erwerbspreis von $0 aus und werden in direktem Eigentum gehalten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lorber Timothy J.
(Last) (First) (Middle)
C/O SHUTTLE PHARMACEUTICALS HOLDINGS
401 PROFESSIONAL DRIVE, SUITE 260
(Street)
GAITHERSBURG MD 20879
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 08/08/2025 A 29,240 (2) (2) Common Stock 29,240 $0 29,240 D
Restricted Stock Unit (1) 08/08/2025 A 24,854 (3) (3) Common Stock 24,854 $0 24,854 D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU"s) represents the contingent right to receive one share of common stock.
2. One-third of these RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028.
3. These RSUs will vest on 02/08/2026.
/s/ Timothy J Lorber 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What RSU grants were reported for Shuttle Pharmaceuticals (SHPH) on this Form 4?

The filing reports grants totaling 54,094 RSUs to CFO Timothy J. Lorber: 29,240 RSUs and 24,854 RSUs.

When do the RSUs granted to Timothy J. Lorber vest?

The 29,240 RSUs vest one-third on 08/08/2026, 08/08/2027, and 08/08/2028. The 24,854 RSUs vest on 02/08/2026.

What is the reported acquisition price for the RSUs on the SHPH Form 4?

The reported acquisition price for the RSU awards is $0.

What is Timothy J. Lorber's relationship to Shuttle Pharmaceuticals (SHPH)?

The Form 4 identifies Timothy J. Lorber as an Officer with the title Chief Financial Officer.

Are the RSU awards held directly or indirectly according to the filing?

Both RSU awards are reported with ownership form Direct (D) in Table II.

What does each Restricted Stock Unit represent in this filing?

The filing states that each Restricted Stock Unit (RSU) represents the contingent right to receive one share of common stock.
Stock SHPH logo
SHUTTLE PHARMACTCLS HLDGS INC

NASDAQ:SHPH

SHPH Rankings

#6489 Ranked by Market Cap
N/A Ranked by Dividends

SHPH Latest News

Aug 14, 2025
Shuttle Pharma Provides Second Quarter 2025 Corporate Update
Jun 24, 2025
Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market
Jun 20, 2025
Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
Jun 12, 2025
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
Jun 12, 2025
Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

SHPH Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G/A] Shuttle Pharmaceuticals Holdings, Inc. SEC Filing
Aug 12, 2025
[10-Q] Shuttle Pharmaceuticals Holdings, Inc. Quarterly Earnings Report
Aug 13, 2025
[Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity
Aug 12, 2025
[Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity
Aug 12, 2025
[Form 4] Shuttle Pharmaceuticals Holdings, Inc. Insider Trading Activity

SHPH Stock Data

1.66M
1.01M
5.82%
0.84%
8.82%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
GAITHERSBURG